Santaris leads with a $48.3M round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Santaris Pharma
|
$48.3M
|
ABN AMRO Capital Life Sciences |
Santaris has specialized in developing RNA Antagonist drugs based on Locked Nucleic Acid. |
|
Helicos BioSciences
|
$40M
|
Flagship Ventures, Atlas Ventures, Highland Capital, MPM Capital, and Versant Ventures |
The money will support of the company's development of the company's "true Single Molecule Sequencing" technologies and techniques. |
|
Egalet
|
$27.6M
|
Atlas Venture and Index Ventures |
Egalet is a delivery company focused on developing oral controlled-release products. |
|
BioXell
|
€10.5M
|
TVM Capital |
The funds will support the company's development schedule. |
|
APT Pharmaceuticals
|
$9M
|
Charter Life Sciences and Research Corporation Technologies |
The capital will be used to accelerate the company's pulmonary and nasal clinical development programs. |